If you purchased Sun Pharmaceutical Industries and Ranbaxy Inc. products including generic Nexium and generic or branded Diovan and Valcyte, you may be eligible for this settlement. There are both nationwide classes and state-based classes. The “Indirect Purchaser States” are: Arizona, California, the District of Columbia, Florida, Hawaii, Iowa, Massachusetts, Maine, Michigan, Minnesota, Missouri, Nebraska, Nevada, New Hampshire, New Mexico, North Carolina, North Dakota, Oregon, South Dakota, Vermont, West Virginia, and Wisconsin. If you’re not in one of these states, you still may qualify for the nationwide class. The products that are currently included are Nexium, Valcyte and Diovan. The current payout is approximately $145,000,000. There is no proof required at this time. The deadline to file a claim is October 11, 2022. Visit the link below to get started.